Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Clinical Trials Compassionate Use Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
Press Releases Our latest press releases are available to read here Press Releases Date Range Explore Search Press Releases / 04 Jun 2023 Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023 Press Releases / 01 Jun 2023 Ivonescimab Updated Data to be Featured at ASCO 2023 Press Releases / 11 May 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023 Press Releases / 09 May 2023 Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112) Press Releases / 03 May 2023 Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112) Press Releases / 09 Mar 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022 Press Releases / 03 Mar 2023 Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering Press Releases / 23 Feb 2023 Summit Therapeutics’ Rights Offering Nearing Expiration Date Press Releases / 30 Jan 2023 Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million Press Releases / 20 Jan 2023 Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody Press Releases / 05 Jan 2023 Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Press Releases / 06 Dec 2022 Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody 1 2 … 31 32 >>
Press Releases / 04 Jun 2023 Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023 Press Releases / 01 Jun 2023 Ivonescimab Updated Data to be Featured at ASCO 2023 Press Releases / 11 May 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023 Press Releases / 09 May 2023 Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112) Press Releases / 03 May 2023 Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112) Press Releases / 09 Mar 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022 Press Releases / 03 Mar 2023 Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering Press Releases / 23 Feb 2023 Summit Therapeutics’ Rights Offering Nearing Expiration Date Press Releases / 30 Jan 2023 Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million Press Releases / 20 Jan 2023 Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody Press Releases / 05 Jan 2023 Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Press Releases / 06 Dec 2022 Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Press Releases / 04 Jun 2023 Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
Press Releases / 11 May 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
Press Releases / 09 May 2023 Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
Press Releases / 03 May 2023 Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
Press Releases / 09 Mar 2023 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Press Releases / 03 Mar 2023 Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
Press Releases / 30 Jan 2023 Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million
Press Releases / 20 Jan 2023 Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
Press Releases / 05 Jan 2023 Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Press Releases / 06 Dec 2022 Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks